EAS Lipoprotein(a) Workshop

This course aims to provide a solid understanding of lipoprotein(a) [Lp(a)], including its molecular structure and its role in the development of atherosclerosis. It covers the underlying pathophysiology and epidemiology of Lp(a), as well as methods for its measurement and interpretation in clinical practice. Additionally, it outlines how to perform a comprehensive cardiovascular disease (CVD) risk assessment and reviews current guidelines for the clinical management of elevated Lp(a) levels.

Course structure

This programme comprises three presentations. Every presentation takes approximately 20–30 minutes. Once you’ve listened to all the presentations you will be asked to answer multiple choice questions on them. You need to achieve a score of at least 80% correct to pass.

Language

Presentations are given in English. Subtitles are available in English, German and Italian.

Details

Date of preparation: March 26, 2026
Last revised: March 26, 2026
Expiry date: March 26, 2028

By the end of this course, participants will be able to:

• Describe the structure and function of lipoprotein(a) [Lp(a)], including its molecular composition and role in atherogenesis, thrombosis, and vascular inflammation.
• Explain the pathophysiology and epidemiology of Lp(a), including its genetic determinants, population distribution, and contribution to atherosclerotic cardiovascular disease (ASCVD) risk.
• Measure and interpret Lp(a) levels, including understanding laboratory methods, unit standardization (mg/dL vs nmol/L), indications for testing, and clinical relevance of results.
• Perform a comprehensive cardiovascular disease (CVD) risk assessment, integrating Lp(a) into existing risk models to identify high-risk individuals.
• Apply current clinical guidelines to the management of elevated Lp(a), including risk thresholds, treatment strategies, and awareness of emerging therapies.

This course is designed for medical specialists, with a focus on managing patients with dyslipidaemias. It is especially relevant for:

• Healthcare providers focused on dyslipidaemia management and risk stratification
• Cardiologists and lipidologists managing patients with cardiovascular risk
• Endocrinologists and internists monitoring metabolic and lipid disorders
• Specialists in clinical chemistry or laboratory medicine involved in Lp(a) testing
• Preventive medicine and primary care professionals assessing CVD risk